Skip to content
Menu

Adicet Bio, Inc. ACET

Full chart Compare
Set alert

Price alert · ACET

All alert types
2.46 USD -0.04 (-1.60%)

Regular-session close

2.44 -0.02 -0.81%

After hours · Nov 19, 4:00 PM ET

2.42 Day range 2.62
2.40 52-week range 11.15
YTD
-70.78%
1 year
-73.35%

 

No chart data for this range yet.
Market cap
23.03M
EPS (ttm)
-7.47
Shares out
82.40M
Forward P/E
-0.69
YTD return
-70.78%
1-year return
-73.35%
50-day average
1.16
200-day average
1.48
Enterprise value
-97.82M
Volume
281.23K
Avg volume
257.05K
Open
2.49
Previous close
2.50
Day's range
2.42 – 2.62
52-week range
2.40 – 11.15
Beta
1.70
Analysts
Buy
Price target
6.40 (+160.2%)

Key statistics

Price / book
0.23
Free cash flow
-55.26M
Total cash
224.07M
Total debt
19.13M
Return on equity
-57.91%
Short % of float
4.93%

Fundamental scorecard

5 of 25 checks passed on ACET’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ACET Revenue — quarterly 0
ACET Net income — quarterly -18.88M
ACET EPS — quarterly -1.76

Upgrades / downgrades

ACET analyst upgrades and downgrades
DateFirmActionFromTo
Dec 19, 2024HC Wainwright & Co.reitNeutralNeutral
Nov 18, 2024HC Wainwright & Co.reit—Neutral
Aug 14, 2024HC Wainwright & Co.reitBuyBuy
Aug 14, 2024Canaccord GenuitymainBuyBuy
Jul 8, 2024HC Wainwright & Co.reitBuyBuy
Jun 24, 2024HC Wainwright & Co.reitBuyBuy

About Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ACET — it syncs with the Stock Master app.

Insider holders

ACET insider holders
InsiderRelationLatest transactionDateShares held
CHODAKEWITZ JEFFREYDirectorStock Award(Grant)Jun 4, 202411,800
DUBIN STEVEDirectorStock Award(Grant)Jun 4, 202416,800
GORDON CARL LDirector and Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Jun 4, 202411,458,900
HARVEY BRIAN NICHOLASChief Financial OfficerStock Award(Grant)Jan 23, 202499,800
JAKOBOVITS AYADirectorStock Award(Grant)Jun 4, 2024862,562
KAUFFMAN MICHAEL GDirectorSaleJun 4, 20245,900

Institution ownership

ACET institution ownership
Holder% heldSharesValueReported
Orbimed Advisors LLC.13.89%11,447,14010.49MSep 29, 2024
Tang Capital Management, LLC9.97%8,216,9607.53MSep 29, 2024
RA Capital Management, L.P.9.15%7,541,0006.91MSep 29, 2024
Goldman Sachs Group Inc4.56%3,759,9973.44MSep 29, 2024
Vanguard Group Inc3.89%3,205,8822.94MSep 29, 2024
Carlyle Group Inc.3.58%2,948,7182.70MSep 29, 2024

Fund ownership

ACET fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.51%2,072,1011.90MSep 29, 2024
Vanguard Extended Market Index Fund1.31%1,079,499989.04KSep 29, 2024
Bridgeway Funds Inc-Ultra Small Company Fund0.80%660,300604.97KSep 29, 2024
Fidelity Extended Market Index Fund0.43%351,417321.97KOct 30, 2024
Fidelity Enhanced Small Cap ETF0.27%222,485203.84KOct 30, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.23%191,300175.27KSep 29, 2024